PLA2G2C encodes a calcium-dependent phospholipase A2 group IIC protein that functions as an inactive phospholipase 1. The gene maps to human chromosome 1-p36.1 and is tightly linked with related phospholipase A2 genes 1. Unlike its rodent ortholog, human PLA2G2C appears to be a nonfunctional pseudogene 1. However, PLA2G2C maintains functional relevance through regulatory mechanisms rather than catalytic activity. Genetic variants in PLA2G2C, particularly rs2301475, influence plasma triglyceride levels during omega-3 polyunsaturated fatty acid supplementation, suggesting involvement in lipid metabolism 2. PLA2G2C expression is induced in response to Aspergillus fumigatus challenge in cystic fibrosis models, implicating it in inflammatory and allergic responses 3. DNA methylation at the PLA2G2C locus (cg04605617) is significantly associated with both arsenic exposure and QT interval prolongation, a cardiac electrophysiological phenotype 45. The methylation quantitative trait locus rs10916683 at cg04605617 acts as a strong eQTL for PLA2G2C, suggesting epigenetic regulation influences gene expression and downstream cardiovascular effects 5. These findings indicate PLA2G2C may serve as a novel therapeutic target for preventing QT interval prolongation and managing environmental toxin exposure.